Abstract: The present disclosure provides isolated monoclonal antibodies or an antigen-binding portion thereof that specifically bind to CD40 preferably human CD40 with high affinity, and that function as CD40 agonists. The disclosed invention also relates to antibodies that are chimeric, humanized, bispecific, derivatized, single chain antibodies or portions of fusion proteins. Nucleic acid molecules encoding the antibodies of the disclosed invention, hybridoma, and methods for expressing the antibodies of the disclosed invention are also provided. Pharmaceutical compositions comprising the antibodies of the disclosed invention are also provided. This disclosure also provides methods for regulating humoral and cellular immune responses, as well as methods for treating cancer using an anti-CD40 agonist antibody of the disclosed invention.

Abstract: An isolated bispecific antibody or antigen-binding portion thereof includes a first chain which specifically binds to human PD-1(hPD-1) and blocks the interaction between hPD-1 and PD-L1, and a second chain which specifically binds to human CD47 and inhibits its interaction with SIRP-alpha, where the first chain and the second chain are coupled in a knob-in-hole format through their respective CH3 domain.

Abstract: The present disclosure provides isolated monoclonal antibodies or antigen-binding portions thereof that specifically bind to CD47 preferably human CD47 with high affinity, and can enhance tumor-targeting immune response by therapeutically boosting the phagocytic function of macrophage for cancer treatment. The disclosure also provides antibodies that are chimeric, humanized, bispecific, derivatized, single chain antibodies or portions of fusion proteins. Nucleic acid molecules encoding the antibodies of the disclosed invention and hybridoma are also provided. Pharmaceutical compositions comprising the antibodies of the disclosed invention are also provided. This disclosure also provides methods for regulating innate immune responses, as well as methods for treating cancer using an anti-CD47 antagonist antibody of the disclosed invention.

Abstract: The present disclosure provides isolated monoclonal antibodies or an antigen-binding portion thereof that specifically bind to CD40 preferably human CD40 with high affinity, and that function as CD40 agonists. The disclosed invention also relates to antibodies that are chimeric, humanized, bispecific, derivatized, single chain antibodies or portions of fusion proteins. Nucleic acid molecules encoding the antibodies of the disclosed invention, hybridoma, and methods for expressing the antibodies of the disclosed invention are also provided. Pharmaceutical compositions comprising the antibodies of the disclosed invention are also provided. This disclosure also provides methods for regulating humoral and cellular immune responses, as well as methods for treating cancer using an anti-CD40 agonist antibody of the disclosed invention.

Abstract: The present disclosure provides isolated monoclonal antibodies or an antigen-binding portion thereof that specifically bind to CD40 preferably human CD40 with high affinity, and that function as CD40 agonists. The disclosed invention also relates to antibodies that are chimeric, humanized, bispecific, derivatized, single chain antibodies or portions of fusion proteins. Nucleic acid molecules encoding the antibodies of the disclosed invention, hybridoma, and methods for expressing the antibodies of the disclosed invention are also provided. Pharmaceutical compositions comprising the antibodies of the disclosed invention are also provided. This disclosure also provides methods for regulating humoral and cellular immune responses, as well as methods for treating cancer using an anti-CD40 agonist antibody of the disclosed invention.

Abstract: Adjuvant compositions, vaccines, constructs for preparing the adjuvant compositions and vaccines and methods of using the adjuvant compositions and vaccines to enhance immune responses in subjects are provided herein. In particular, a rapid antibody response to the vaccine including both IgG (in the circulation) and sIgA (mucosal secretory IgA) is elicited. The adjuvants and vaccines may be used for sub-cutaneous or mucosal administration enabling low cost, effective vaccination of subjects. A method of epitope mapping to rapidly identify antigenic epitopes is also provided.

Abstract: A capacitive touch system uses at least two first integrated circuits to simultaneously scan a touch panel, each of the first integrated circuits only for scanning a portion of the touch panel to retrieve the sensed data from its responsible traces. Therefore, the capacitive touch system can maintain a good frame rate, even the touch panel is a large scale touch panel. A data transmission method transmits only the non-zero sensed values to a second integrated circuit where a calculation with the non-zero sensed values is executed, and thereby reduces the data transmission time.

Abstract: A capacitive touch system uses at least two integrated circuits to simultaneously scan a touch panel, each scanning only a portion of traces of the touch panel, and a second integrated circuit to receive sensed data from the first integrated circuits. The sensed data contains parameters representing a sum of the sensed values of all traces in a direction that one of the first integrated circuits is in charge of scanning, a sum of products obtained by multiplying the sensed value of each trace in the direction that the one of the first integrated circuits scans by the order number of that trace, a number of fingers in the direction detected by the one of the first integrated circuits, and whether or not the sensed values of the first and last traces in the direction that the one of the first integrated circuits scans are zero.

Abstract: A capacitive touch system uses at least two first integrated circuits to simultaneously scan a touch panel, each of the first integrated circuits only for scanning a portion of the touch panel to retrieve the sensed data from its responsible traces. Therefore, the capacitive touch system can maintain a good frame rate, even the touch panel is a large scale touch panel. A data transmission method transmits only the non-zero sensed values to a second integrated circuit where a calculation with the non-zero sensed values is executed, and thereby reduces the data transmission time.

Abstract: A capacitive touch system uses at least two integrated circuits to simultaneously scan a touch panel, each of the integrated circuits scanning only a portion of the touch panel. If any one of the integrated circuits has not detected any objects on its scanning zone for a long time, it will enter a suspend mode to lower the scanning frequency thereof for power saving.

Abstract: A capacitive touch system uses at least two integrated circuits to simultaneously scan a touch panel, each scanning only a portion of traces of the touch panel, and a second integrated circuit to receive sensed data from the first integrated circuits. The sensed data contains parameters representing a sum of the sensed values of all traces in a direction that one of the first integrated circuits is in charge of scanning, a sum of products obtained by multiplying the sensed value of each trace in the direction that the one of the first integrated circuits scans by the order number of that trace, a number of fingers in the direction detected by the one of the first integrated circuits, and whether or not the sensed values of the first and last traces in the direction that the one of the first integrated circuits scans are zero.

Abstract: A capacitive touch system uses at least two first integrated circuits to simultaneously scan a touch panel, each of the first integrated circuits only for scanning a portion of the touch panel. Therefore, the capacitive touch system can maintain a good frame rate, even the touch panel is a large scale touch panel. Each of the first integrated circuits transmits its sensed data to a second integrated circuit where a calculation with the received sensed data is executed. The second integrated circuit has at least a common pin connected to each of the first integrated circuits, and therefore the number of pins of the second integrated circuit is reduced.